Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | FSHR | P23945 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9812184 | 0.90 | RXRA (0.32) | TSHR | |
| SCHEMBL9230922 | 0.88 | MEN1 (0.36) | TP53SMN1; SMN2MAPTMEN1ADRB2 | |
| SCHEMBL9232043 | 0.85 | MEN1 (0.38) | TP53SMN1; SMN2MAPTMEN1ADRB2 | |
| SCHEMBL9232359 | 0.85 | MEN1 (0.41) | TP53SMN1; SMN2MAPTMEN1ADRB2 | |
| SCHEMBL9226784 | 0.82 | FSHR (0.35) | TP53MAPTMEN1ADRB2KMT2A | |
| SCHEMBL9228015 | 0.80 | FSHR (0.36) | TP53SMN1; SMN2MAPTMEN1ADRB2 | |
| SCHEMBL15197890 | 0.80 | TP53 (0.39) | TP53SMN1; SMN2MAPTMEN1ADRB2 | |
| SCHEMBL7930754 | 0.80 | TP53 (0.37) | TP53SMN1; SMN2MAPTMEN1ADRB2 | |
| SCHEMBL9230073 | 0.79 | FSHR (0.39) | TP53SMN1; SMN2MAPTMEN1ADRB2 | |
| SCHEMBL9232039 | 0.72 | PDK2 (0.33) | TP53MAPTMEN1ADRB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017435-B2 | Process for the preparation of a phenylindan compound | IGH RESINS ITALIA S.R.L. | 2018-07-10 | — | — | US | disclosed |
| US-20180141882-A1 | PROCESS FOR THE PREPARATION OF A PHENYLINDAN COMPOUND | IGM RESINS ITALIA S.R.L. (IT) | 2018-05-24 | — | — | US | disclosed |
| US-9765006-B2 | Process for the preparation of a phenylindan photoinitiator | IGM RESINS ITALIA S.R.L. (IT) | 2017-09-19 | — | — | US | disclosed |
| US-20170152202-A1 | PROCESS FOR THE PREPARATION OF A PHENYLINDAN PHOTOINITIATOR | IGM RESINS ITALIA S.R.L. (IT) | 2017-06-01 | — | — | US | disclosed |
| US-20120029238-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE MIXTURES OF ALPHA-HYDROXYCARBONYL DERIVATIVES OF ALPHA-METHYLSTYRENE DIMERS | IGM RESINS ITALIA S.R.L. (IT) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017435-B2 | Process for the preparation of a phenylindan compound | CYP1A1, HPD, CYP1B1 | TP53 4649/4885SMN1; SMN2 3515/4885MAPT 1897/4885 |
| US-20180141882-A1 | PROCESS FOR THE PREPARATION OF A PHENYLINDAN COMPOUND | CYP1A1, HPD, CYP1B1 | TP53 4649/4885SMN1; SMN2 3515/4885MAPT 1897/4885 |
| US-20120029238-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE MIXTURES OF ALPHA-HYDROXYCARBONYL DERIVATIVES OF ALPHA-METHYLSTYRENE DIMERS | POLL, RAD52, DPY30 | TP53 515/4885SMN1; SMN2 2940/4885MAPT 1385/4885 |
| US-20170152202-A1 | PROCESS FOR THE PREPARATION OF A PHENYLINDAN PHOTOINITIATOR | CYP1A1, CYP1B1, CYP1A2 | TP53 4417/4885SMN1; SMN2 4424/4885MAPT 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.